{"id":"omalizumab-cinnagen","safety":{"commonSideEffects":[{"rate":"45","effect":"Injection site reaction"},{"rate":"15","effect":"Headache"},{"rate":"20","effect":"Upper respiratory tract infection"},{"rate":"8","effect":"Arthralgia"},{"rate":"10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201589","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By sequestering free IgE, omalizumab reduces the activation of mast cells and basophils that would otherwise occur upon allergen exposure. This suppression of the allergic cascade reduces the release of inflammatory mediators such as histamine, tryptase, and cytokines, thereby decreasing allergic symptoms and airway hyperresponsiveness in allergic asthma and other IgE-mediated conditions.","oneSentence":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:07.546Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe allergic asthma"},{"name":"Chronic idiopathic urticaria"},{"name":"Nasal polyposis"}]},"trialDetails":[{"nctId":"NCT05813470","phase":"PHASE3","title":"Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2021-01-18","conditions":"Allergic Asthma, Uncontrolled Moderate to Severe","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zerafil®"],"phase":"phase_3","status":"active","brandName":"Omalizumab (CinnaGen)","genericName":"Omalizumab (CinnaGen)","companyName":"Cinnagen","companyId":"cinnagen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Nasal polyposis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}